Topic

#brezosiran

1 story

#alnylam-pharmaceuticals #huntingtons-disease #rnai-therapy #biotechnology

Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript

Alnylam Pharmaceuticals held an RNAi roundtable discussing exon 1 targeting with Brezosiran for Huntington's Disease. This event highlights ongoing research and development in treating neurodegenerative diseases using RNA interference technology.

6.5K13511